Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04888806
Other study ID # SHR-1210-HLJ-019
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date June 1, 2021
Est. completion date June 30, 2025

Study information

Verified date May 2021
Source Harbin Medical University
Contact Yanqiao Zhang, Ph D
Phone 13845120210
Email yanqiaozhang@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Currently, comprehensive treatments for liver metastasis/pulmonary metastasis that cannot reach NED include systemic chemotherapy, interventional chemotherapy, molecular targeted therapy, immunotherapy, and local treatments (ablation therapy, radiation therapy, etc.) for liver metastases. Combination therapy model of local ablation, systemic chemotherapy, and anti-PD -1 monoclonal antibody hopefully can prolong patient survival. This trial will evaluate the effectiveness and safety of carrelizumab combined with microwave ablation and chemotherapy in the treatment of colorectal cancer liver metastasis/pulmonary metastasis


Description:

This is a phase II, single-arm prospective trial of local ablation combined with chemotherapy and camrelizumab for liver metastasis/pulmonary metastasis in colorectal cancer. The enrolled patients received ablation of liver metastases/pulmonary metastasis first, followed by chemotherapy (standard treatment plan for advanced colorectal cancer, determined by the investigator) and camrelizumab treatment (200mg, iv, q3w) one week later. If the patient has multiple metastatic tumors, ablation therapy needs to be performed in multiple times. Sequential chemotherapy and camrelizumab is administered one week after each ablation therapy. Treatment will continue until disease progression, unacceptable toxicity, or voluntary patient withdrawal.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 37
Est. completion date June 30, 2025
Est. primary completion date June 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1. Two types of imaging or histology/cytology confirmed colorectal cancer patients with liver metastasis/lung metastasis ; 2. Must have CT or MRI examination for the past 3 months; 3. In addition to ablation lesions, there are measurable metastatic lesions (spiral CT scan =10mm, meet mRECIST 1.1 standard); 4. Expected survival time> 3 months; 5. Patients who have received at least one prior systemic treatment; 6. The damage caused by the subject receiving other treatments has been restored; 7. Known KRAS, NRAS, BRAF and HER2 gene status; 8. Age: 18 to 70 years old, no gender limit; 9. ECOG PS: 0-2 points; 10. The functions of vital organs meet the following requirements: 1. .Absolute neutrophil count =1.5×109/L, platelet =100×109/L, hemoglobin =9g/dL; 2. . Bilirubin =1.5 times ULN (can be included in patients drained by retrograde technique); ALT and AST =5 times ULN 3. . Creatinine <120µmol/ L, or MDRD creatinine clearance rate> 60 mL/min 11. Women of childbearing age must have a negative pregnancy test (ßHCG) before starting treatment, Women and men of childbearing age (have sex with women of childbearing age) must agree to use effective contraception during treatment and for 6 months after the last treatment dose is administered 12. Signature of patient information and informed consent Exclusion Criteria: 1. Women who are pregnant or breastfeeding, or have fertility but refuse to take contraceptive measures; 2. Suffer from other malignant tumors within 5 years, except for fully treated cervical carcinoma in situ or skin squamous cell carcinoma, or skin basal cell carcinoma that has been basically controlled; 3. Those with uncontrolled, symptomatic brain metastases or a history of uncontrollable mental illness or severe intellectual or cognitive dysfunction; 4. Subjects with active, known or suspected autoimmune diseases, hypothyroidism requiring only hormone replacement therapy, skin diseases that do not require systemic treatment (such as vitiligo, psoriasis, or hair loss) Can be selected 5. Patients with active hepatitis B or C, chronic infection of hepatitis B virus (HBV) or hepatitis C virus (HCV) with a viral load of less than 500 IU/mL are allowed to participate in the study, but need to continue during the study period or start a full-course standardized antiviral treatment; 6. Congestive heart failure, uncontrollable arrhythmia, myocardial infarction, unstable angina, stroke or transient ischemic attack within 6 months; or other patients who cannot tolerate surgery; 7. Severe active infections that require intravenous antibiotic treatment occurred during the enrollment period; 8. Those who are allergic to test drugs; 9. Live vaccines have been vaccinated or will be vaccinated within 30 days before the administration of Camrelizumab; 10. Patients who cannot comply with the trial protocol or cannot cooperate with follow-up; 11. The researcher believes that it is inappropriate to participate in this trial.

Study Design


Intervention

Drug:
Camrelizumab
d1,200mg, iv, q3w
Procedure:
ablation
the 37 enrolled patients received ablation of liver/lung metastases ,If the patient has multiple metastatic tumors, ablation therapy needs to be performed in multiple times.
Drug:
chemotherapy
standard treatment plan for mCRC, determined by the investigator

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Harbin Medical University

Outcome

Type Measure Description Time frame Safety issue
Primary 12-month progression-free survival (PFS) The date of first treatment until the date of progression using the RECIST 1.1 criteria, or death due to any cause,whichever comes first. 1 year
Secondary Objective response rate(ORR) ORR, which is defined as the proportion of subjects who achieve a best response of complete response(CR) or partial response (PR) using the RECIST 1.1 criteria. 3 years
Secondary Disease control rate (DCR) DCR, which is defined as the proportion of subjects who achieve a response of complete response, partial response and stable disease (CR+PR+SD) in the total number of evaluable subjects using the RECIST 1.1 criteria. 3 years
Secondary progression-free survival (PFS) The date of first treatment until the date of progression using the RECIST 1.1 3 years
Secondary Overall Survival(OS) Overall Survival, defined from the date of first treatment to the date of death due to any cause. 3 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03781934 - A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations Phase 1/Phase 2
Completed NCT02107755 - Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma Phase 2
Recruiting NCT05057052 - Cryoablation Combined With Sintilimab Plus Regorafenib In Previously Treated Colorectal Cancer Liver Metastasis Phase 2
Recruiting NCT06120127 - Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence Phase 2
Recruiting NCT04837885 - Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases Phase 2
Terminated NCT04589884 - Intraoperative EXamination Using MAChine-learning-based HYperspectral for diagNosis & Autonomous Anatomy Assessment
Not yet recruiting NCT04520737 - Multimodal Prehabilitation During Chemotherapy in Patients With Colorectal Liver Metastases N/A
Terminated NCT02465112 - Metabolic Radiotherapy After Complete Resection of Liver Metastases in Patient With Digestive Neuroendocrine Tumor Phase 3
Completed NCT02352259 - Treatment of Liver Metastases With Electrochemotherapy (ECTJ) Phase II Phase 2
Active, not recruiting NCT01763450 - Bevacizumab Therapy Untreated Unresectable Liver Metastases From Colorectal Cancer Phase 2
Withdrawn NCT01631539 - Chemoembolisation With CPT11 Loaded DC Bead With Cetuximab and 5FU/LV in First Line in Patients With KRAS Wildtype mCRC N/A
Recruiting NCT01250158 - Liver-PILP First-in-Man N/A
Terminated NCT01233544 - Radiofrequency Ablation Versus Stereotactic Radiotherapy in Colorectal Liver Metastases Phase 3
Completed NCT01347333 - Stereotactic Body Radiotherapy for Liver Tumors N/A
Completed NCT01683357 - Prognosis of One-stage Hepatectomy for Bilobar Colorectal Metastases N/A
Completed NCT00587756 - Alternative to Two-Stage Hepatectomy N/A
Completed NCT04942665 - Low Dose ICG for Biliary Tract and Tumor Imaging Phase 2
Not yet recruiting NCT05354674 - Multimodal Deep Learning Signature for Evaluation of Response to Bevacizumab in Patient With Colorectal Cancer Liver Metastasis
Recruiting NCT04616495 - Liver Transplantation in Patients With Unresectable Colorectal Liver Metastases
Not yet recruiting NCT04509635 - Cetuximab Re-challenge for Colorectal Cancer Liver Metastasis Phase 3